STENTYS initiates the Commercialization of the first Self-Expanding Drug-Eluting stent for the Below-The-Knee Indication
PRINCETON, N.J. and PARIS., STENTYS, a medical technology company
commercializing the world's first and only Self-Apposing® coronary stent, today
announces the first distribution agreements for its drug-eluting stent for
treating BTK (Below-The Knee) arteries in Germany and Belgium, making it the
first self-expanding drug eluting stent commercialized for this indication in
Europe.
The STENTYS stent obtained CE Marking for the BTK indication at the end of 2015 following the excellent results achieved by the PES BTK-70 study, where it prevented amputation in 99% of the 70 patients treated for Critical Limb Ischemia (CLI). The rapid launch of its commercialization reflects a major medical need, particularly in Germany, Europe’s largest market.
Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, comments: “We are delighted by the interest we received for our stent, the first in Europe to combine the benefits of self-expansion and drug-elution in the BTK indication. The peripheral artery disease market, currently estimated to be worth 1.3 billion dollars outside the United States and Japan and driven by the growing global prevalence of diabetes, represents a major growth driver for STENTYS.”
Source: Stentys
Comments